Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825238 | 0.89 | AVPR1A (0.59) | AVPR1AHSD11B1CNR1OPRM1OPRK1 | |
| SCHEMBL825327 | 0.89 | AVPR1A (0.47) | AVPR1AHSD11B1CNR1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL829428 | 0.88 | AVPR1A (0.46) | AVPR1AHSD11B1CNR1OPRM1OPRK1 | |
| SCHEMBL825145 | 0.87 | AVPR1A (0.50) | AVPR1AHSD11B1CNR1 | |
| SCHEMBL825148 | 0.86 | AVPR1A (0.59) | AVPR1AHSD11B1CNR1OPRM1OPRK1 | |
| SCHEMBL828756 | 0.86 | AVPR1A (0.47) | AVPR1AHSD11B1CNR1OPRM1OPRK1 | |
| SCHEMBL825277 | 0.86 | OXTR (0.49) | AVPR1AHSD11B1 | |
| SCHEMBL825146 | 0.84 | OXTR (0.50) | AVPR1AHSD11B1CNR1OPRM1OPRK1 | |
| SCHEMBL825323 | 0.83 | OPRM1 (0.45) | AVPR1AHSD11B1CNR1OPRM1OPRK1 | |
| SCHEMBL27786396 | 0.81 | HSD11B1 (0.43) | AVPR1AHSD11B1CNR1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125785-B1 | INDOLE-3-YL-CARBONYL-PIPERIDINE- DERIVATIVES FOR THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS VIA V1A RECEPTOR ANTAGONISM | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | claimed |
| WO-2011132443-A1 | SURFACE ACOUSTIC WAVE DEVICE AND MANUFACTURING METHOD OF SAME | 株式会社村田製作所 (JP) | 2011-10-27 | — | — | WO | claimed |
| EP-2125785-A1 | INDOLES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | claimed |
| CN-101583609-A | Indoles | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | CN | claimed |
| WO-2008080842-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | claimed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | claimed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2125785-B1 | INDOLE-3-YL-CARBONYL-PIPERIDINE- DERIVATIVES FOR THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS VIA V1A RECEPTOR ANTAGONISM | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| EP-2125785-B1 | INDOLE-3-YL-CARBONYL-PIPERIDINE- DERIVATIVES FOR THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS VIA V1A RECEPTOR ANTAGONISM | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011132443-A1 | SURFACE ACOUSTIC WAVE DEVICE AND MANUFACTURING METHOD OF SAME | 株式会社村田製作所 (JP) | 2011-10-27 | — | — | WO | disclosed |
| EP-2125785-A1 | INDOLES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008080842-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161315-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885HSD11B1 916/4885CNR1 31/4885 |
| US-20080161316-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885HSD11B1 916/4885CNR1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.